RPHM Reneo Pharmaceuticals Inc.

7.03
-0.69  -9%
Previous Close 7.72
Open 7.41
52 Week Low 6.1
52 Week High 17.1799
Market Cap $171,700,017
Shares 24,423,900
Float 10,934,526
Enterprise Value $30,818,508
Volume 15,482
Av. Daily Volume 32,252
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
REN001
McArdle disease
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
REN001-102
Long-chain fatty acid oxidation disorders (LC-FAOD)
Phase 1b
Phase 1b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
REN001 (STRIDE)
Primary mitochondrial myopathies (PMM)
Phase 2b
Phase 2b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. IRVINE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended September 30, 2021 and provided an update on its clinical programs.

    "We continued to make good progress across multiple fronts during the third quarter of 2021," said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. "We initiated the global PMM Phase 2b study, completed enrollment of the LC-FAOD Phase 1b study, and anticipate completion of enrollment of the LC-FAOD natural history study by year-end 2021. In addition, we…

    IRVINE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended September 30, 2021 and provided an update on its clinical programs.

    "We continued to make good progress across multiple fronts during the third quarter of 2021," said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. "We initiated the global PMM Phase 2b study, completed enrollment of the LC-FAOD Phase 1b study, and anticipate completion of enrollment of the LC-FAOD natural history study by year-end 2021. In addition, we expanded our leadership team by making several key hires, including the appointment of Ashley Hall, J.D., as Chief Development Officer. Finally, we strengthened our REN001 patent portfolio with the recent notice of allowance for a key composition of matter patent in the United States," concluded Mr. Flesher.

    Key Operational Highlights

    • Initiated enrollment of STRIDE, a global, double-blind, randomized, placebo-controlled Phase 2b trial of REN001 in patients with PMM
    • Completed enrollment in REN001-102, an open-label Phase 1b clinical trial in patients with LC-FAOD
    • Appointed Ashley Hall as Chief Development Officer to lead nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management
    • Received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a composition of matter patent application covering the REN001 drug substance. The patent application is expected to issue as a patent in 2022 and to provide patent protection for REN001 in the United States into 2041.

    Financial Results for the Three Months Ended September 30, 2021

    The company reported a net loss of $12.7 million, or $0.52 per share, for the three months ended September 30, 2021, compared to a net loss of $5.1 million, or $2.48 per share, for the same period in 2020. The company had $157.7 million in cash, cash equivalents and short-term investments as of September 30, 2021.

    Research and development expenses for the three months ended September 30, 2021 were $9.3 million, compared to $4.4 million for the three months ended September 30, 2020. This increase of $4.9 million was primarily due to an increase of $2.1 million related to clinical trial and manufacturing costs associated with the launch of our STRIDE and FORWARD studies as well as the restart of our Phase 1b clinical trials of LC-FAOD and McArdle disease, a $2.0 million increase in licensing costs and a $0.7 million increase in employee and personnel related costs due to additional headcount required to support our clinical and CMC programs.

    General and administrative expenses for the three months ended September 30, 2021 were $3.4 million, compared to $0.7 million during the three months ended September 30, 2020. This increase of $2.7 million was primarily attributable to an increase of $1.8 million in employee and personnel related expenses, consisting of $1.0 million of stock-based compensation and $0.8 million of employee compensation as a result of increased headcount, an increase of $0.4 million of directors and officers' insurance premiums following our initial public offering and an increase of $0.6 million for outside professional services.

    Anticipated Upcoming Milestones

    • Results of the Phase 1b clinical trial of REN001 in McArdle disease (1Q 2022)
    • Results of the Phase 1b clinical trial of REN001 in LC-FAOD (2Q 2022)
    • Results of the FORWARD natural history study in LC-FAOD (2Q 2022)

    Upcoming Corporate Access Events

    • Credit Suisse 30th Annual Healthcare Conference, November 8 - 11, 2021
    • Jefferies 12th Annual London Healthcare Conference, November 16 – 19, 2021
    • Piper Sandler 33rd Annual Healthcare Conference, November 30 – December 2, 2021

    About Reneo Pharmaceuticals

    Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

    About REN001

    REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for three rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disorder type V (McArdle disease). For more information on REN001 clinical trials, please see clinicaltrials.gov.

    About PMM

    PMM are a group of disorders that affect roughly 1 in 5,000 people worldwide. PMM are caused by genetic mutations in the mitochondrial or nuclear DNA that reduce the ability of mitochondria to produce energy from nutrient sources. This energy deficit particularly affects tissues and organs with high energy demand such as muscle, brain, and heart. The symptoms of PMM include muscle weakness or exercise intolerance, movement disorder, deafness, blindness, and droopy eyelids among others. The prognosis for these disorders ranges in severity from progressive weakness to death.

    About STRIDE

    STRIDE is a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial designed to assess the efficacy and safety of 100 mg REN001 administered orally once daily to patients with PMM. Approximately 200 adult PMM patients with alterations in mitochondrial DNA and a history of myopathy are expected to be enrolled into STRIDE. The primary efficacy endpoint of the trial is the change from baseline in the distance walked during a 12-minute walk test after 24 weeks of treatment. Secondary efficacy endpoints include changes from baseline in the Modified Fatigue Impact Scale (MFIS), Patient Global Impression of Change scale (PGIC), and other patient-reported outcomes.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the results, conduct, progress and timing of Reneo's clinical trials, the regulatory approval path for REN001 and patent issuance and protection matters. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans," "will," "believes," "anticipates," "expects," "intends," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo's business in general, and the other risks described in Reneo's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.





    RENEO PHARMACEUTICALS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and par value data)

          
     SEPTEMBER 30, DECEMBER 31,
     2021  2020 
     (unaudited)   
    Assets     
    Current assets:     
    Cash and cash equivalents$126,409  $53,613 
    Short-term investments 31,325    
    Prepaid expenses and other current assets 4,931   1,412 
    Total current assets 162,665   55,025 
    Property and equipment, net 200   69 
    Other non-current assets 78   127 
    Total assets$162,943  $55,221 
    Liabilities, convertible preferred stock and stockholders' equity (deficit)     
    Current liabilities:     
    Accounts payable$1,271  $908 
    Accrued expenses 5,082   3,672 
    Total current liabilities 6,353   4,580 
    Deferred rent 98   36 
    Performance Award 284    
    Total liabilities 6,735   4,616 
    Commitments and contingencies     
    Series A convertible preferred stock, $0.0001 par value; zero and 24,302,472 shares authorized at September 30, 2021 and December 31, 2020, respectively; zero and 24,302,472 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of $0 and $49,127 at September 30, 2021 and December 31, 2020, respectively    45,652 
    Series B convertible preferred stock, $0.0001 par value; zero and 46,881,028 shares authorized at September 30, 2021 and December 31, 2020, respectively; zero and 23,440,514 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of $0 and $47,385 as of September 30, 2021 and December 31, 2020, respectively    47,068 
    Stockholders' equity (deficit):     
    Preferred stock, $0.0001 par value, 10,000,000 and zero shares authorized at September 30, 2021 and December 31, 2020, respectively; zero shares issued and outstanding as of September 30, 2021 and December 31, 2020     
    Common stock, $0.0001 par value; 200,000,000 and 105,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 24,417,558 and 24,407,722 shares issued and outstanding at September 30, 2021, respectively and 2,053,070 shares issued and outstanding at December 31, 2020 3    
    Additional paid-in capital 230,309   2,843 
    Accumulated deficit (74,121)  (44,958)
    Accumulated other comprehensive income 17    
    Total stockholders' equity (deficit) 156,208   (42,115)
    Total liabilities, convertible preferred stock and stockholders' equity (deficit)$162,943  $55,221 





    RENEO PHARMACEUTICALS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited)

    (in thousands, except share and per share data)

                
     THREE MONTHS ENDED SEPTEMBER 30, NINE MONTHS ENDED SEPTEMBER 30,
     2021  2020  2021  2020 
    Operating expenses:           
    Research and development$9,318  $4,431  $21,069  $10,826 
    General and administrative 3,434   668   8,125   2,475 
    Total operating expenses 12,752   5,099   29,194   13,301 
    Loss from operations (12,752)  (5,099)  (29,194)  (13,301)
    Other income 17   5   31   89 
    Net loss (12,735)  (5,094)  (29,163)  (13,212)
    Unrealized gain (loss) on short-term investments 12   (4)  17    
    Comprehensive loss$(12,723) $(5,098) $(29,146) $(13,212)
    Net loss per share attributable to common stockholders, basic and diluted$(0.52) $(2.48) $(1.82) $(6.54)
    Weighted-average shares used in computing net loss per share, basic and diluted 24,396,798   2,052,838   16,025,813   2,021,031 





    RENEO PHARMACEUTICALS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited)

    (in thousands)

          
     NINE MONTHS ENDED
     SEPTEMBER 30,
     2021  2020 
    Cash flows from operating activities     
    Net loss$(29,163) $(13,212)
    Adjustments to reconcile net loss to net cash used in operating activities:     
    Depreciation and amortization 33   27 
    Amortization/accretion on short-term investments 113   (17)
    Changes in the fair value of performance award 284    
    Stock-based compensation 2,470   264 
    Changes in operating assets and liabilities:     
    Accounts payable, accrued expenses and other 1,816   20 
    Prepaid expenses and other assets (3,577)  (203)
    Deferred rent 62   (4)
    Net cash used in operating activities (27,962)  (13,125)
    Cash flows from investing activities     
    Purchases of property and equipment (108)  (8)
    Purchase of available-for-sale short-term investments (31,421)   
    Proceeds from maturities of available-for-sale short-term investments    7,400 
    Net cash (used in) provided by investing activities (31,529)  7,392 
    Cash flows from financing activities     
    Proceeds from issuance of Series B convertible preferred stock, net of issuance costs 47,239    
    Proceeds from initial public offering, net of offering costs 84,641    
    Proceeds from exercise of stock options 407   77 
    Net cash provided by financing activities 132,287   77 
    Net increase (decrease) in cash and cash equivalents 72,796   (5,656)
    Cash and cash equivalents, beginning of period 53,613   17,501 
    Cash and cash equivalents, end of period$126,409  $11,845 
    Supplemental cash flow information:     
    Vesting of unvested exercised options$19  $ 
    Property and equipment in accounts payable$56  $ 



    Contacts:

    Joyce Allaire

    Managing Director

    LifeSci Advisors, LLC



    Vinny Jindal

    Chief Financial Officer

    Reneo Pharmaceuticals, Inc.



    Primary Logo

    View Full Article Hide Full Article
  2. IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be participating in the following investors conferences during the month of November.

    Conference and presentation details are as follows:

    Credit Suisse 30th Annual Healthcare Conference (November 8-11, 2021)
    Format: Presentation and one-on-one's
    Date: Thursday, November 11th, 2021
    Time: 12:10-12:50 PM ET

    Piper Sandler 33rd Healthcare Conference (November 30-December 2, 2021)
    Format: Fireside chat (on-demand)
    Date: Monday, November 22nd, 2021

    A link to our presentation…

    IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be participating in the following investors conferences during the month of November.

    Conference and presentation details are as follows:

    Credit Suisse 30th Annual Healthcare Conference (November 8-11, 2021)

    Format: Presentation and one-on-one's

    Date: Thursday, November 11th, 2021

    Time: 12:10-12:50 PM ET

    Piper Sandler 33rd Healthcare Conference (November 30-December 2, 2021)

    Format: Fireside chat (on-demand)

    Date: Monday, November 22nd, 2021

    A link to our presentation from the Credit Suisse Healthcare Conference will be posted on the "Investors" section of the Reneo Pharmaceuticals corporate website, under Events and Presentations.

    About Reneo Pharmaceuticals

    Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

    Contacts:

    Joyce Allaire

    Managing Director

    LifeSci Advisors, LLC

    Vinny Jindal

    Chief Financial Officer

    Reneo Pharmaceuticals, Inc.



    Primary Logo

    View Full Article Hide Full Article
  3. IRVINE, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application No. 17/381,005. The composition of matter patent application covers the REN001 drug substance. REN001 is currently being studied in patients with primary mitochondrial myopathy, as well as other rare genetic mitochondrial diseases. The patent application is expected to issue as a patent at the earliest in 2021 and will provide patent protection for REN001…

    IRVINE, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application No. 17/381,005. The composition of matter patent application covers the REN001 drug substance. REN001 is currently being studied in patients with primary mitochondrial myopathy, as well as other rare genetic mitochondrial diseases. The patent application is expected to issue as a patent at the earliest in 2021 and will provide patent protection for REN001 in the United States into 2041.

    A notice of allowance is a written notification issued after the USPTO makes a determination that a patent can be granted from an application. The majority of patent applications that receive a notice of allowance will proceed to issue as a U.S. patent. However, a notice of allowance is not a guarantee of patent issuance.

    About Reneo Pharmaceuticals

    Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria.

    About REN001

    REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for three rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disorder type V (McArdle disease). For more information on REN001 clinical trials, please see clinicaltrials.gov.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the expected patent issuance and the period of patent protection. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans," "will," "believes," "anticipates," "expects," "intends," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with patent issuances, risks and uncertainties associated with Reneo's business in general, and the other risks described in Reneo's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Contacts:

    Joyce Allaire

    Managing Director

    LifeSci Advisors, LLC

    Vinny Jindal

    Chief Financial Officer

    Reneo Pharmaceuticals, Inc.

     



    Primary Logo

    View Full Article Hide Full Article
  4. IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. Hall, JD, to the position of Chief Development Officer. In this role, Ms. Hall will oversee nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management for all the company's development programs.

    "We are happy to welcome Ashley to the Reneo leadership team," said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. "Ashley is an experienced leader in the biopharmaceutical industry, with…

    IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. Hall, JD, to the position of Chief Development Officer. In this role, Ms. Hall will oversee nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management for all the company's development programs.

    "We are happy to welcome Ashley to the Reneo leadership team," said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. "Ashley is an experienced leader in the biopharmaceutical industry, with a track record of successfully bringing multiple novel drug products to market in the U.S., Europe, and other regions of the world. Her deep understanding of the drug development process will be instrumental in the development of REN001."

    "I am very excited to be joining the extraordinary team at Reneo," said Ms. Hall. "REN001 has the potential to benefit patients suffering from a range of diseases driven by mitochondrial dysfunction. I look forward to working with the Reneo team to advance this important product through the next series of critical milestones."

    Ms. Hall brings more than 20 years of experience in global drug development to Reneo. Prior to joining Reneo, Ms. Hall was the Chief Development Officer and Head of Global Regulatory Affairs at Esperion Therapeutics, where she successfully led the regulatory approvals of the company's two lead cholesterol lowering products, Nexletol® and Nexlizet®, in major markets around the world. Prior to joining Esperion, Ms. Hall was the Global Regulatory Lead at Amgen, overseeing the regulatory strategy and global filings for the Repatha® program, which led to the world's first approval of a PCSK9 inhibitor for cholesterol lowering. Prior to Esperion, Ms. Hall was the Vice President of Regulatory Affairs at Micromet (acquired by Amgen) where she led the Blincyto® rare disease oncology program. Ms. Hall also held prior leadership roles at RevoGenex, MedImmune (acquired by AstraZeneca), and Abraxis BioScience.

    Ms. Hall earned a Juris Doctorate (JD) from the University of San Diego School of Law and a Bachelor of Science in biochemistry and cell biology, with a minor in philosophy (bioethics), from the University of California, San Diego.

    In connection with Ms. Hall's employment with the company, Ms. Hall will be granted inducement awards consisting of an option to purchase 180,000 shares of common stock, plus a restricted stock unit award covering 30,000 shares of common stock. The Compensation Committee of Reneo's Board of Directors approved the awards as inducements material to Ms. Hall's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

    About Reneo Pharmaceuticals

    Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria.

    About REN001

    REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for three rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disorder type V (McArdle disease). For more information on REN001 clinical trials, please see clinicaltrials.gov.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the advancement of REN001 development programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans," "will," "believes," "anticipates," "expects," "intends," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo's business in general, and the other risks described in Reneo's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Contacts:

    Joyce Allaire

    Managing Director

    LifeSci Advisors, LLC

    Vinny Jindal

    Chief Financial Officer

    Reneo Pharmaceuticals, Inc.



    Primary Logo

    View Full Article Hide Full Article
  5. IRVINE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will host a key opinion leader (KOL) webinar on McArdle Disease and other genetic mitochondrial myopathies on Monday, October 4, 2021, at 12 pm Eastern Time.

    This webinar will feature KOL Rosaline Quinlivan, M.D., from the National Hospital for Neurology and Neurosurgery, Queen Square, London, who is the current clinical lead for the nationally commissioned service for McArdle disease and related disorders. Dr. Quinlivan will discuss the current treatment landscape…

    IRVINE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will host a key opinion leader (KOL) webinar on McArdle Disease and other genetic mitochondrial myopathies on Monday, October 4, 2021, at 12 pm Eastern Time.

    This webinar will feature KOL Rosaline Quinlivan, M.D., from the National Hospital for Neurology and Neurosurgery, Queen Square, London, who is the current clinical lead for the nationally commissioned service for McArdle disease and related disorders. Dr. Quinlivan will discuss the current treatment landscape, patient journey, and unmet medical need for patients with McArdle disease and other genetic mitochondrial myopathies.

    Reneo's Chief Medical Officer, Dr. Alex Dorenbaum, will also discuss the Company's clinical program for its lead candidate, REN001, in the treatment of McArdle Disease. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may also increase production of new mitochondria.

    Dr. Quinlivan and the Reneo management team will be available to answer questions following the formal presentations.

    To register for the webinar, please click here.

    Professor Rosaline Quinlivan BSc (hons), MBBS, DCH, FRCPCH, FRCP, MD developed and leads the Neuromuscular Complex Care Centre, which includes services for young adults transitioning from pediatric care. She also leads a national service for McArdle disease and related disorders at The National Hospital for Neurology and Neurosurgery, Queen Square, London. Her training was in pediatric neuromuscular disease and her post-graduate M.D. thesis was on the cardiomyopathy of Duchenne and Becker muscular dystrophy. Prior to moving to London in 2010, she was director of the Wolfson Centre for Neuromuscular Disease and consultant at RJAH Orthopaedic and Birmingham Children's Hospitals. She has been principal investigator for a number of clinical trials in DMD, centronuclear myopathy, and McArdle disease. She leads the U.K. Adult North Star Network for DMD and is chair of the British Myology Society. She is the joint coordinating editor for the Cochrane Neuromuscular Disease Group.

    About Reneo Pharmaceuticals

    Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria.

    Contacts:

    Joyce Allaire

    Managing Director

    LifeSci Advisors, LLC

    Vinny Jindal

    Chief Financial Officer

    Reneo Pharmaceuticals, Inc.



    Primary Logo

    View Full Article Hide Full Article
View All Reneo Pharmaceuticals Inc. News